These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

156 related items for PubMed ID: 23583031

  • 21. Solid phase synthesis of aminoboronic acids: potent inhibitors of the hepatitis C virus NS3 proteinase.
    Dunsdon RM, Greening JR, Jones PS, Jordan S, Wilson FX.
    Bioorg Med Chem Lett; 2000 Jul 17; 10(14):1577-9. PubMed ID: 10915055
    [Abstract] [Full Text] [Related]

  • 22. Substrate-based peptidomimetic inhibitors of the Murray Valley encephalitis virus NS2B/NS3 serine protease: a P1-P4 SAR study.
    Ang MJ, Yong GH, Poulsen A, Then SW, Li Z, Joy J, Hill J, Chia CS.
    Eur J Med Chem; 2013 Oct 17; 68():72-80. PubMed ID: 23974013
    [Abstract] [Full Text] [Related]

  • 23. Design, synthesis, and anti-HCV activity of thiourea compounds.
    Kang IJ, Wang LW, Lee CC, Lee YC, Chao YS, Hsu TA, Chern JH.
    Bioorg Med Chem Lett; 2009 Apr 01; 19(7):1950-5. PubMed ID: 19251415
    [Abstract] [Full Text] [Related]

  • 24. Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimization.
    Prongay AJ, Guo Z, Yao N, Pichardo J, Fischmann T, Strickland C, Myers J, Weber PC, Beyer BM, Ingram R, Hong Z, Prosise WW, Ramanathan L, Taremi SS, Yarosh-Tomaine T, Zhang R, Senior M, Yang RS, Malcolm B, Arasappan A, Bennett F, Bogen SL, Chen K, Jao E, Liu YT, Lovey RG, Saksena AK, Venkatraman S, Girijavallabhan V, Njoroge FG, Madison V.
    J Med Chem; 2007 May 17; 50(10):2310-8. PubMed ID: 17444623
    [Abstract] [Full Text] [Related]

  • 25. Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design.
    Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J.
    J Med Chem; 2005 Aug 11; 48(16):5088-91. PubMed ID: 16078825
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Design, synthesis, and evaluation of oxygen-containing macrocyclic peptidomimetics as inhibitors of HCV NS3 protease.
    Velázquez F, Venkatraman S, Blackman M, Pinto P, Bogen S, Sannigrahi M, Chen K, Pichardo J, Hart A, Tong X, Girijavallabhan V, Njoroge FG.
    J Med Chem; 2009 Feb 12; 52(3):700-8. PubMed ID: 19154150
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Novel potent hepatitis C virus NS3 serine protease inhibitors derived from proline-based macrocycles.
    Chen KX, Njoroge FG, Arasappan A, Venkatraman S, Vibulbhan B, Yang W, Parekh TN, Pichardo J, Prongay A, Cheng KC, Butkiewicz N, Yao N, Madison V, Girijavallabhan V.
    J Med Chem; 2006 Feb 09; 49(3):995-1005. PubMed ID: 16451065
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Inhibitors of hepatitis C virus NS3.4A protease 2. Warhead SAR and optimization.
    Perni RB, Pitlik J, Britt SD, Court JJ, Courtney LF, Deininger DD, Farmer LJ, Gates CA, Harbeson SL, Levin RB, Lin C, Lin K, Moon YC, Luong YP, O'Malley ET, Rao BG, Thomson JA, Tung RD, Van Drie JH, Wei Y.
    Bioorg Med Chem Lett; 2004 Mar 22; 14(6):1441-6. PubMed ID: 15006379
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3.
    Dahl G, Sandström A, Akerblom E, Danielson UH.
    Antivir Ther; 2007 Mar 22; 12(5):733-40. PubMed ID: 17713156
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
    Lampa A, Ehrenberg AE, Gustafsson SS, Vema A, Kerblom E, Lindeberg G, Karlén A, Danielson UH, Sandström A.
    Bioorg Med Chem; 2010 Jul 15; 18(14):5413-24. PubMed ID: 20541424
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.